The essential role of PIM kinases in sarcoma growth and bone invasion

Carcinogenesis

Volumn 33, Issue 8, 2012, Pages 1479-1486

  Narlik Grassow, Maja ^a   Blanco Aparicio, Carmen ^a   Cecilia, Yolanda ^a   Peregrina, Sandra ^a   Garcia Serelde, Beatriz ^a   Mũoz Galvan, Sandra ^b   Cañamero, Marta ^a   Carnero, Amancio ^b,c  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN KINASE PIM 3; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CANCER; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; EMBRYO; ENZYME PHOSPHORYLATION; FIBROBLAST; KNOCKOUT MOUSE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; WESTERN BLOTTING;

ANIMALS; BONE AND BONES; CARCINOGENS; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; METHYLCHOLANTHRENE; MICE; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-PIM-1; SARCOMA, EXPERIMENTAL;

EID: 84865333826     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs176     Document Type: Article

References (62)

1. Nawijn, M.C. et al. (2011) For better or for worse: the role of Pim oncogenes in tumourigenesis. Nat. Rev. Cancer, 11, 23-34.
2. Amaravadi, R. et al. (2005) The survival kinases Akt and Pim as potential pharmacological targets. J. Clin. Invest., 115, 2618-2624.
3. Brault, L. et al. (2010) PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica, 95, 1004-1015.
4. Eichmann, A. et al. (2000) Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene, 19, 1215-1224.
5. Bullock, A.N. et al. (2005) Structure and substrate specificity of the Pim-1 kinase. J. Biol. Chem., 280, 41675-41682.
6. Mukaida, N. et al. (2011) Roles of Pim-3, a novel survival kinase, in tumourigenesis. Cancer Sci., 102, 1437-1442.
7. Mikkers, H. et al. (2004) Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol. Cell Biol., 24, 6104-6115.
8. Dautry, F. et al. (1988) Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. J. Biol. Chem., 263, 17615-17620.
9. Fox, C.J. et al. (2003) The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev., 17, 1841-1854.
10. Xu, D. et al. (2011) The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. Carcinogenesis, 32, 488-495.
11. Allen, J.D. et al. (1997) Pim-2 transgene induces lymphoid tumours, exhibiting potent synergy with c-myc. Oncogene, 15, 1133-1141.
12. Allen, J.D. et al. (1996) Complementation tagging of cooperating oncogenes in knockout mice. Semin. Cancer Biol., 7, 299-306.
13. Selten, G. et al. (1986) The primary structure of the putative oncogene pim-1 shows extensive homology with protein kinases. Cell, 46, 603-611.
14. Cuypers, H.T. et al. (1986) Assignment of the human homologue of Pim-1, a mouse gene implicated in leukemogenesis, to the pter-q12 region of chromosome 6. Hum. Genet., 72, 262-265.
15. Wang, Z. et al. (2001) Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumourigenesis. J. Vet. Sci., 2, 167-179.
16. Shah, N. et al. (2008) Potential roles for the PIM1 kinase in human cancer -a molecular and therapeutic appraisal. Eur. J. Cancer, 44, 2144-2151.
17. Bachmann, M. et al. (2005) The serine/threonine kinase Pim-1. Int. J. Biochem. Cell Biol., 37, 726-730.
18. Nga, M.E. et al. (2010) PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications. Int. J. Exp. Pathol., 91, 34-43.
19. Mumenthaler, S.M. et al. (2009) Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol. Cancer Ther., 8, 2882-2893.
20. Chen, J. et al. (2009) Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene, 28, 2581-2592.
21. Chen, J. et al. (2009) Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumour formation. Am. J. Pathol., 175, 400-411.
22. Breuer, M. et al. (1989) Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice. Nature, 340, 61-63.
23. van Lohuizen, M. et al. (1989) Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumours. Cell, 56, 673-682.
24. Lilly, M. et al. (1997) Enforced expression of the Mr 33, 000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res., 57, 5348-5355.
25. Lilly, M. et al. (1999) The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene, 18, 4022-4031.
26. Domen, J. et al. (1993) Impaired interleukin-3 response in Pim-1-deficient bone marrow-derived mast cells. Blood, 82, 1445-1452.
27. Yan, B. et al. (2003) The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J. Biol. Chem., 278, 45358-45367.
28. Paukku, K. et al. (2004) STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev., 15, 435-455.
29. Aho, T.L. et al. (2006) Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity. BMC Cell Biol., 7, 21.
30. Wang, Z. et al. (2002) Phosphorylation of the cell cycle inhibitor p21Cip1/ WAF1 by Pim-1 kinase. Biochim. Biophys. Acta, 1593, 45-55.
31. Morishita, D. et al. (2008) Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res., 68, 5076-5085.
32. Mochizuki, T. et al. (1999) Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J. Biol. Chem., 274, 18659-18666.
33. Koike, N. et al. (2000) Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1). FEBS Lett., 467, 17-21.
34. Evans, K.E. et al. (2007) Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol., 8, 4.
35. Rainio, E.M. et al. (2002) Cutting edge: transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J. Immunol., 168, 1524-1527.
36. Winn, L.M. et al. (2003) Pim-1 phosphorylates the DNA binding domain of c-Myb. Cell Cycle, 2, 258-262.
37. Ishibashi, Y. et al. (2001) Pim-1 translocates sorting nexin 6/TRAF4-associated factor 2 from cytoplasm to nucleus. FEBS Lett., 506, 33-38.
38. Laird, P.W. et al. (1993) In vivo analysis of Pim-1 deficiency. Nucleic Acids Res., 21, 4750-4755.
39. Domen, J. et al. (1993) Analysis of Pim-1 function in mutant mice. Leukemia, 7 (suppl. 2), S108-112.
40. Magnuson, N.S. et al. (2010) Why target PIM1 for cancer diagnosis and treatment? Future Oncol., 6, 1461-1478.
41. Carnero, A. et al. (2000) Loss-of-function genetics in mammalian cells: the p53 tumour suppressor model. Nucleic Acids Res., 28, 2234-2241.
42. Carnero, A. et al. (2004) Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation. Oncogene, 23, 6006-6011.
43. Guijarro, M.V. et al. (2007) MAP17 enhances the malignant behavior of tumour cells through ROS increase. Carcinogenesis, 28, 2096-2104.
44. Leal, J.F. et al. (2008) Cellular senescence bypass screen identifies new putative tumour suppressor genes. Oncogene, 27, 1961-1970.
45. Blanco-Aparicio, C. et al. (2011) Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Lett., 300, 145-153.
46. Beharry, Z. et al. (2009) Novel benzylidene-thiazolidine-2, 4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol. Cancer Ther., 8, 1473-1483.
47. Wu, Y. et al. (2010) Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver. Oncogene, 29, 2228-2237.
48. Carnero, A. (2010) The PKB/AKT pathway in cancer. Curr. Pharm. Des., 16, 34-44.
49. Acosta, J.C. et al. (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell, 133, 1006-1018.
50. Bachmann, M. et al. (2004) The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J. Biol. Chem., 279, 48319-48328.
51. Zhang, Y. et al. (2007) Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol. Cancer Res., 5, 909-922.
52. Vivanco, I. et al. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2, 489-501.
53. Hernandez, F. et al. (2010) Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol. Cell Biochem., 344, 211-215.
54. Mora, A. et al. (2002) Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A. Cell Signal., 14, 557-562.
55. Ivaska, J. et al. (2002) Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta. Mol. Cell Biol., 22, 1352-1359.
56. Chen, W.W. et al. (2005) Pim family kinases enhance tumour growth of prostate cancer cells. Mol. Cancer Res., 3, 443-451.
57. Santio, N.M. et al. (2010) Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. Mol. Cancer, 9, 279.
58. Zhang, P. et al. (2009) Pim-3 is expressed in endothelial cells and promotes vascular tube formation. J. Cell Physiol., 220, 82-90.
59. Grundler, R. et al. (2009) Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J. Exp. Med., 206, 1957-1970.
60. Mancini, M. et al. (2009) NFAT proteins: emerging roles in cancer progression. Nat. Rev. Cancer, 9, 810-820.
61. Qian, K.C. et al. (2005) Expression, purification, crystallization and preliminary crystallographic analysis of human Pim-1 kinase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 61, 96-99.
62. Pogacic, V. et al. (2007) Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res., 67, 6916-6924.